Quectel’s Ultra-high Bandwidth 5G R16 Module Certified for Use on T-Mobile’s 5G and LTE-A Networks
14.9.2022 18:41:00 EEST | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, has announced that its 5G NR module RM520N-GL, compliant with 3GPP Release 16 (R16) standards, has been certified to operate on T-Mobile’s 5G and LTE-A networks in the United States.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220829005280/en/
Quectel's 5G module RM520N-GL and its IoT application scenarios (Photo: Business Wire)
With this certification, RM520N-GL customers can commercially deploy their home gateways, industrial routers, industrial automation devices, unmanned delivery vehicles, robots, drones, consumer and industrial laptops and other next generation IoT applications on T-Mobile’s 5G and LTE-A networks.
“We are thrilled to see that Quectel has made further significant progress in 5G, as our module supporting 5G R16 features has gained this important certification in the North American market,” said Norbert Muhrer, President and CSO of Quectel. “This confirms our commitment to drive innovation and provide our global customers with highly reliable, best-in-class IoT solutions, which will help accelerate the next wave of 5G IoT applications.”
Based on Qualcomm’s SDX62 platform, the RM520N-GL supports both 5G NSA and SA modes, as well as R16 enhanced features such as ultra-high bandwidth, millisecond-level latency, 5G network slicing and ultra-reliability.
Targeting global markets, this module is designed to support 28 major sub-6GHz bands worldwide (n1/ 2/ 3/ 5/ 7/ 8/ 12/ 13/ 14/ 18/ 20/ 25/ 26/ 28/ 29/ 30/ 38/ 40/ 41/ 48/ 66/ 70/ 71/ 75/ 76/ 77/ 78/ 79), is backwards compatible with LTE-A/3G networks and features integrated GNSS for location services. This highly integrated module can significantly enhance customers' global IoT deployments.
Designed in an industry-standard M.2 form factor, the dimensions of the RM520N-GL are 30.0mm x 52.0mm x 2.3mm, making it pin-to-pin compatible with Quectel’s 5G module RM50xQ series, LTE-A Cat 6 module EM06/ EM060K series, Cat 12 modules EM12/ EM12xR/ EM120K series and Cat 16 module EM160R-GL, which facilitates easy network upgrades of customer devices.
The RM520N-GL supports downlink and uplink NR 2 x Carrier Aggregation (CA) and all three combinations of sub-6GHz time division duplex (TDD) and frequency division duplex (FDD) CA, including CA of FDD+TDD, FDD+FDD and TDD+TDD. This ensures greater 5G coverage, capacity and throughput by enabling the combination of available 5G spectrum assets. These features enable the RM520N-GL to have maximum downlink rates of up to 3.4Gbps and maximum uplink rates of up to 900Mbps. These data rates meet the needs of industry applications requiring enhanced mobile broadband and reliable communication capabilities, such as fixed wireless access (FWA), mobile broadband equipment and industrial automation.
Featuring a rich set of internet protocols, the RM520N-GL supports multiple optional functions including eSIM and VoLTE and integrates USB 3.1/ PCIe 3.0 super speed interfaces.
In addition to the T-Mobile approval, Quectel’s RM520N-GL has also achieved worldwide certification from GCF, PTCRB, CE, CCC, RCM, FCC and IC.
In order to help customers simplify their designs, Quectel also provides a full range of off-the-shelf and customized 5G antennas which boost wireless connectivity significantly. IoT developers can bundle the RM520N-GL module with Quectel’s antennas and pre-certification services, reducing both cost and time-to-market for their 5G devices.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth® modules, antennas and IoT connectivity. With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.Quectel.com, LinkedIn, Facebook, and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220829005280/en/
Contact information
Media
Ashley Liu – media@quectel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom